Immune interaction between SARS-CoV-2 and Mycobacterium tuberculosis
- Author(s)
- Booysen, P; Wilkinson, KA; Sheerin, D; Waters, R; Coussens, AK; Wilkinson, RJ;
- Journal Title
- Frontiers in Immunology
- Abstract
- SARS-CoV-2 and Mycobacterium tuberculosis (Mtb) are major infectious causes of death, with meta-analyses and population-based studies finding increased mortality in co-infected patients simultaneously diagnosed with COVID-19 and tuberculosis (TB). There is a need to understand the immune interaction between SARS-CoV-2 and Mtb which impacts poor outcomes for those co-infected. We performed a PubMed and preprint search using keywords [SARS-CoV-2] AND [tuberculosis] AND [Immune response], including publications after January 2020, excluding reviews or opinions. Abstracts were evaluated by authors for inclusion of data specifically investigating the innate and/or acquired immune responses to SARS-CoV-2 and Mtb in humans and animal models, immunopathological responses in co-infection and both trials and investigations of potential protection against SARS-CoV-2 by Bacille Calmette Guérin (BCG). Of the 248 articles identified, 39 were included. Incidence of co-infection is discussed, considering in areas with a high burden of TB, where reported co-infection is likely underestimated. We evaluated evidence of the clinical association between COVID-19 and TB, discuss differences and similarities in immune responses in humans and in murine studies, and the implications of co-infection. SARS-CoV-2 and Mtb have both been shown to modulate immune responses, particularly of monocytes, macrophages, neutrophils, and T cells. Co-infection may result in impaired immunity to SARS-CoV-2, with an exacerbated inflammatory response, while T cell responses to Mtb may be modulated by SARS-CoV-2. Furthermore, there has been no proven potential COVID-19 clinical benefit of BCG despite numerous large-scale clinical trials.
- Publisher
- Frontiers
- Keywords
- Humans; Animals; Mice; *Mycobacterium tuberculosis; SARS-CoV-2; *covid-19; *Coinfection; *Tuberculosis/prevention & control; Bacille Calmette Guérin; Covid-19; Ltbi; T cells; co-infection; immune response; latent TB; transcriptomics
- Research Division(s)
- Infectious Diseases And Immune Defence
- PubMed ID
- 37841282
- Publisher's Version
- https://doi.org/10.3389/fimmu.2023.1254206
- Open Access at Publisher's Site
https://doi.org/10.3389/fimmu.2023.1254206- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2023-11-15 05:00:03
Last Modified: 2023-11-15 05:14:00